TriangleHEALTH PROFESSIONAL · SOURCE READING
Zanubrutinib and obinutuzumab
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Evidence (zanubrutinib and obinutuzumab):
A randomized, multicenter, phase II study (ROSEWOOD [NCT03332017]) included 217 patients with relapsed or refractory follicular lymphoma after receiving two or more prior lines of therapy. Patients received either the oral Bruton tyrosine kinase inhibitor zanubrutinib plus obinutuzumab or obinutuzumab alone until disease progression.[23][Level of evidence B1]
Source links and citations
A randomized, multicenter, phase II study (ROSEWOOD [NCT03332017]) included 217 patients with relapsed or refractory follicular lymphoma after receiving two or more prior lines of therapy. Patients received either the oral Bruton tyrosine kinase inhibitor zanubrutinib plus obinutuzumab or obinutuzumab alone until disease progression.[23][Level of evidence B1]
With a median follow-up of 19.0 months, the median PFS was 28.0 months for patients who received zanubrutinib plus obinutuzumab and 10.4 months for patients who received obinutuzumab alone (HR, 0.50; 95% CI, 0.33–0.75; P < .001).
A randomized, multicenter, phase II study (ROSEWOOD [NCT03332017]) included 217 patients with relapsed or refractory follicular lymphoma after receiving two or more prior lines of therapy. Patients received either the oral Bruton tyrosine kinase inhibitor zanubrutinib plus obinutuzumab or obinutuzumab alone until disease progression.[23][Level of evidence B1]
The overall response rate was 69% (95% CI, 61%–76%) in the zanubrutinib-plus-obinutuzumab arm and 46% (95% CI, 34%–58%) in the obinutuzumab-alone arm (P = .0012).
The U.S. Food and Drug Administration approved zanubrutinib and obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more prior lines of therapy.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice